New Review Endorses CV Benefits of Fish Oil
y discuss the results for each specific cardiovascular condition in turn. For CHF, three large randomized trials — the Diet and Reinfarction Trial (DART), the Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico (GISSI)-Prevenzione, and the Japan EPA Lipid Intervention Study (JELIS) — have indicated that omega-3 PUFAs lower CV risk in both the primary- and secondary-prevention settings, they note.
Lavie elaborated to heartwire : "The benefit is different in different studies but can be as much as 30%." The effects are seen on total mortality, sudden death, CHD mortality, and cardiovascular mortality.
But there are some studies that have not shown favorable results, although there are generally methodological reasons for this, they say. However, they do flag the most recent study of post-MI patients, OMEGA, which suggests there may not be additional short-term benefit of omega-3 PUFAs in low-risk patients already receiving optimal modern therapy.
Dr. Lavie has been a consultant and speaker for Reliant, Pfizer, Bristol-Myers Squibb, and Sanofi-Aventis and is a speaker receiving honoraria from and on the speaker's bureau of GlaxoSmithKline, Abbott, and Solvay. Disclosures for the coauthors are listed in the article.
References
1.Lavie CJ, Milani RV, Mehra MR, et al. Omega-3 polyunsaturated fatty acids and cardiovascular disease. J Am Coll Cardiol 2009; 54: 585-594. Available at: http://content.onlinejacc.org.
Lavie elaborated to heartwire : "The benefit is different in different studies but can be as much as 30%." The effects are seen on total mortality, sudden death, CHD mortality, and cardiovascular mortality.
But there are some studies that have not shown favorable results, although there are generally methodological reasons for this, they say. However, they do flag the most recent study of post-MI patients, OMEGA, which suggests there may not be additional short-term benefit of omega-3 PUFAs in low-risk patients already receiving optimal modern therapy.
Dr. Lavie has been a consultant and speaker for Reliant, Pfizer, Bristol-Myers Squibb, and Sanofi-Aventis and is a speaker receiving honoraria from and on the speaker's bureau of GlaxoSmithKline, Abbott, and Solvay. Disclosures for the coauthors are listed in the article.
References
1.Lavie CJ, Milani RV, Mehra MR, et al. Omega-3 polyunsaturated fatty acids and cardiovascular disease. J Am Coll Cardiol 2009; 54: 585-594. Available at: http://content.onlinejacc.org.
posted by vanwash at 9:32 PM
0 Comments:
Post a Comment
<< Home